https://doi.org/10.1016/s0140-6736(23)00961-3
W
Wei‐Wen Su
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
142
Papers
4.0K
Citations
28
h-index
60
i10-index
Wei‐Wen Su is an academic researcher from Taichung Veterans General Hospital. The author has contributed to research in topics: Hepatitis C virus research & Liver Disease Diagnosis and Treatment & Hepatitis B Virus Studies. The author has an h-index of 28, co-authored 121 publications.
ORCID: 0000-0001-5554-5938Papers by this author
worksCamrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · The Lancet · 590 citations
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2023 · The Lancet · 415 citations
https://doi.org/10.1016/s0140-6736(23)01796-8
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus‐associated hepatocellular carcinoma in Taiwan
2006 · International Journal of Cancer · 134 citations
https://doi.org/10.1002/ijc.22045
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
2013 · Hepatology · 71 citations
https://doi.org/10.1002/hep.26266
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
2024 · New England Journal of Medicine · 62 citations
https://doi.org/10.1056/nejmoa2405485
Strong association between metabolically-abnormal obesity and gallstone disease in adults under 50 years
2019 · BMC Gastroenterology · 59 citations
https://doi.org/10.1186/s12876-019-1032-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat